Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company's assessment of going concern considerations in accordance with ASC 205-40, "Presentation of Financial Statements-Going Concern," management has determined that the liquidity issues and mandatory liquidation and subsequent dissolution, should the Company be unable to complete a Business Combination by the end of the Completion Window, raise substantial doubt about the Company's ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 24, 2027. The Company's plan to deal with the uncertainty is to complete a Business Combination prior to June 24, 2027 and to receive working capital from its Sponsor. There is no assurance that the Company's plans to consummate a Business Combination or to receive working capital from the Sponsor will be successful.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TDAC
this stock
Translational Development Acquisition Corp.
|
$210.66M | +4.0% | — | — | 0.0% |
|
VYLR
Vylor Inc.
|
$47.55B | — | — | — | 2.2% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$651.33M | +3.3% | — | — | 0.0% |
|
CCXI
Churchill Capital Corp XI
|
$627.18M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TDAC | +0.6% | +1.0% | +2.6% | +0.8% | +4.0% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | +1.3% | +2.4% | +0.1% | -0.6% | -8.5% |
